A citation-based method for searching scientific literature

Shuqiong Wen, Huanzi Lu, Dikan Wang, Junyi Guo, Wenxiao Dai, Zhi Wang. J Leukoc Biol 2021
Times Cited: 5







List of co-cited articles
9 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade.
Brian C Miller, Debattama R Sen, Rose Al Abosy, Kevin Bi, Yamini V Virkud, Martin W LaFleur, Kathleen B Yates, Ana Lako, Kristen Felt, Girish S Naik,[...]. Nat Immunol 2019
575
40

Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms.
Jean-Christophe Beltra, Sasikanth Manne, Mohamed S Abdel-Hakeem, Makoto Kurachi, Josephine R Giles, Zeyu Chen, Valentina Casella, Shin Foong Ngiow, Omar Khan, Yinghui Jane Huang,[...]. Immunity 2020
206
40

An intra-tumoral niche maintains and differentiates stem-like CD8 T cells.
Caroline S Jansen, Nataliya Prokhnevska, Viraj A Master, Martin G Sanda, Jennifer W Carlisle, Mehmet Asim Bilen, Maria Cardenas, Scott Wilkinson, Ross Lake, Adam G Sowalsky,[...]. Nature 2019
264
40

Control of Lymphocyte Fate, Infection, and Tumor Immunity by TCF-1.
Dinesh Raghu, Hai-Hui Xue, Lisa A Mielke. Trends Immunol 2019
43
40

The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes.
Floris Dammeijer, Mandy van Gulijk, Evalyn E Mulder, Melanie Lukkes, Larissa Klaase, Thierry van den Bosch, Menno van Nimwegen, Sai Ping Lau, Kitty Latupeirissa, Sjoerd Schetters,[...]. Cancer Cell 2020
122
40

Exhausted T cells and epigenetic status.
Ziqing Zeng, Feng Wei, Xiubao Ren. Cancer Biol Med 2020
15
40

PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity.
Martin W LaFleur, Thao H Nguyen, Matthew A Coxe, Brian C Miller, Kathleen B Yates, Jacob E Gillis, Debattama R Sen, Emily F Gaudiano, Rose Al Abosy, Gordon J Freeman,[...]. Nat Immunol 2019
72
40

Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy.
Imran Siddiqui, Karin Schaeuble, Vijaykumar Chennupati, Silvia A Fuertes Marraco, Sandra Calderon-Copete, Daniela Pais Ferreira, Santiago J Carmona, Leonardo Scarpellino, David Gfeller, Sylvain Pradervand,[...]. Immunity 2019
494
40

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.
Moshe Sade-Feldman, Keren Yizhak, Stacey L Bjorgaard, John P Ray, Carl G de Boer, Russell W Jenkins, David J Lieb, Jonathan H Chen, Dennie T Frederick, Michal Barzily-Rokni,[...]. Cell 2018
646
40

Chemokines and the immune response to cancer.
Aleksandra J Ozga, Melvyn T Chow, Andrew D Luster. Immunity 2021
66
20


Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin.
Andrew M Intlekofer, Naofumi Takemoto, E John Wherry, Sarah A Longworth, John T Northrup, Vikram R Palanivel, Alan C Mullen, Christopher R Gasink, Susan M Kaech, Joseph D Miller,[...]. Nat Immunol 2005
869
20

LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy.
Mónica Pascual-García, Ester Bonfill-Teixidor, Ester Planas-Rigol, Carlota Rubio-Perez, Raffaella Iurlaro, Alexandra Arias, Isabel Cuartas, Ada Sala-Hojman, Laura Escudero, Francisco Martínez-Ricarte,[...]. Nat Commun 2019
69
20

Regulation and Function of the PD-L1 Checkpoint.
Chong Sun, Riccardo Mezzadra, Ton N Schumacher. Immunity 2018
814
20

4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation.
Qiu-Xia Qu, Xin-Yun Zhu, Wen-Wen Du, Hong-Bin Wang, Yu Shen, Yi-Bei Zhu, Cheng Chen. Front Immunol 2020
12
20

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.
Stefanie N Linch, Michael J McNamara, William L Redmond. Front Oncol 2015
156
20

Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy.
Melvyn T Chow, Aleksandra J Ozga, Rachel L Servis, Dennie T Frederick, Jennifer A Lo, David E Fisher, Gordon J Freeman, Genevieve M Boland, Andrew D Luster. Immunity 2019
220
20

Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1+ Stem-like CD8+ T Cells during Chronic Infection.
William H Hudson, Julia Gensheimer, Masao Hashimoto, Andreas Wieland, Rajesh M Valanparambil, Peng Li, Jian-Xin Lin, Bogumila T Konieczny, Se Jin Im, Gordon J Freeman,[...]. Immunity 2019
168
20

A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells.
Meromit Singer, Chao Wang, Le Cong, Nemanja D Marjanovic, Monika S Kowalczyk, Huiyuan Zhang, Jackson Nyman, Kaori Sakuishi, Sema Kurtulus, David Gennert,[...]. Cell 2016
211
20

T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy.
Laura M Snell, Gloria H Y Lin, Ann J McPherson, Theo J Moraes, Tania H Watts. Immunol Rev 2011
79
20

Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy.
David M Francis, Margaret P Manspeaker, Alex Schudel, Lauren F Sestito, Meghan J O'Melia, Haydn T Kissick, Brian P Pollack, Edmund K Waller, Susan N Thomas. Sci Transl Med 2020
65
20



CXCL9-expressing tumor-associated macrophages: new players in the fight against cancer.
Paola Marie Marcovecchio, Graham Thomas, Shahram Salek-Ardakani. J Immunother Cancer 2021
15
20

RNA velocity of single cells.
Gioele La Manno, Ruslan Soldatov, Amit Zeisel, Emelie Braun, Hannah Hochgerner, Viktor Petukhov, Katja Lidschreiber, Maria E Kastriti, Peter Lönnerberg, Alessandro Furlan,[...]. Nature 2018
20

Exit Strategies: S1P Signaling and T Cell Migration.
Audrey Baeyens, Victoria Fang, Cynthia Chen, Susan R Schwab. Trends Immunol 2015
83
20


Baseline Frequency of Inflammatory Cxcl9-Expressing Tumor-Associated Macrophages Predicts Response to Avelumab Treatment.
Yan Qu, Ji Wen, Graham Thomas, Wenjing Yang, Weiwei Prior, Wenqian He, Purnima Sundar, Xiao Wang, Shobha Potluri, Shahram Salek-Ardakani. Cell Rep 2020
13
20

Tumor necrosis factor receptor/tumor necrosis factor family members in antiviral CD8 T-cell immunity.
Shahram Salek-Ardakani, Michael Croft. J Interferon Cytokine Res 2010
30
20

Molecular and cellular insights into T cell exhaustion.
E John Wherry, Makoto Kurachi. Nat Rev Immunol 2015
20

Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Aizea Morales-Kastresana, Miguel F Sanmamed, Inmaculada Rodriguez, Asis Palazon, Ivan Martinez-Forero, Sara Labiano, Sandra Hervas-Stubbs, Bruno Sangro, Carmen Ochoa, Ana Rouzaut,[...]. Clin Cancer Res 2013
80
20

Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade.
Mohammad Rashidian, Martin W LaFleur, Vincent L Verschoor, Anushka Dongre, Yun Zhang, Thao H Nguyen, Stephen Kolifrath, Amir R Aref, Christie J Lau, Cloud P Paweletz,[...]. Proc Natl Acad Sci U S A 2019
56
20


Integrating single-cell transcriptomic data across different conditions, technologies, and species.
Andrew Butler, Paul Hoffman, Peter Smibert, Efthymia Papalexi, Rahul Satija. Nat Biotechnol 2018
20

Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer.
David B Page, Harry Bear, Sangeetha Prabhakaran, Margaret E Gatti-Mays, Alexandra Thomas, Erin Cobain, Heather McArthur, Justin M Balko, Sofia R Gameiro, Rita Nanda,[...]. NPJ Breast Cancer 2019
36
20

Peripheral T cell expansion predicts tumour infiltration and clinical response.
Thomas D Wu, Shravan Madireddi, Patricia E de Almeida, Romain Banchereau, Ying-Jiun J Chen, Avantika S Chitre, Eugene Y Chiang, Hina Iftikhar, William E O'Gorman, Amelia Au-Yeung,[...]. Nature 2020
211
20

Distinct S1PR roles.
Laurie A Dempsey. Nat Immunol 2019
3
33

T-cell agonists in cancer immunotherapy.
Yeonjoo Choi, Yaoyao Shi, Cara L Haymaker, Aung Naing, Gennaro Ciliberto, Joud Hajjar. J Immunother Cancer 2020
31
20


NFATc1 and NFATc2 together control both T and B cell activation and differentiation.
S L Peng, A J Gerth, A M Ranger, L H Glimcher. Immunity 2001
298
20


IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.
Mark Ayers, Jared Lunceford, Michael Nebozhyn, Erin Murphy, Andrey Loboda, David R Kaufman, Andrew Albright, Jonathan D Cheng, S Peter Kang, Veena Shankaran,[...]. J Clin Invest 2017
20

PD-1 suppresses TCR-CD8 cooperativity during T-cell antigen recognition.
Kaitao Li, Zhou Yuan, Jintian Lyu, Eunseon Ahn, Simon J Davis, Rafi Ahmed, Cheng Zhu. Nat Commun 2021
10
20

Clonal replacement of tumor-specific T cells following PD-1 blockade.
Kathryn E Yost, Ansuman T Satpathy, Daniel K Wells, Yanyan Qi, Chunlin Wang, Robin Kageyama, Katherine L McNamara, Jeffrey M Granja, Kavita Y Sarin, Ryanne A Brown,[...]. Nat Med 2019
505
20


Science gone translational: the OX40 agonist story.
Andrew D Weinberg, Nicholas P Morris, Magdalena Kovacsovics-Bankowski, Walter J Urba, Brendan D Curti. Immunol Rev 2011
101
20

Transcriptional regulator Id2 mediates CD8+ T cell immunity.
Michael A Cannarile, Nicholas A Lind, Richard Rivera, Alison D Sheridan, Kristin A Camfield, Bei Bei Wu, Kitty P Cheung, Zhaoqing Ding, Ananda W Goldrath. Nat Immunol 2006
171
20

Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
Imran G House, Peter Savas, Junyun Lai, Amanda X Y Chen, Amanda J Oliver, Zhi L Teo, Kirsten L Todd, Melissa A Henderson, Lauren Giuffrida, Emma V Petley,[...]. Clin Cancer Res 2020
161
20


Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment.
Helena Harlin, Yuru Meng, Amy C Peterson, Yuanyuan Zha, Maria Tretiakova, Craig Slingluff, Mark McKee, Thomas F Gajewski. Cancer Res 2009
677
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.